BRAF and cancer: Although BRAFV600E is considered a promising therapeutic target for several cancers, especially for BRAF mutation-harboring melanoma [28, 62], the BRAF inhibitor monotherapy was less effective than anticipated in clinical trials of patients with PTC harboring the BRAFV600E mutation [32, 33].